Neurocrine Biosciences (NASDAQ:NBIX) changed -0.61% to recent value of $85.78. The stock transacted 796807 shares during most recent day however it has an average volume of 855.09K shares. It spotted trading -28.31% off 52-week high price. On the other end, the stock has been noted 19.39% away from the low price over the last 52-weeks.
On April 3, 2020, Neurocrine Biosciences (NASDAQ:NBIX) provided an update regarding the company’s business operations during the COVID-19 pandemic as part of its commitment to prioritize the safety, health and well-being of patients, their caregivers, healthcare providers and employees. The company continues to assess any potential impact to its business given the ongoing nature of the pandemic and plans to provide further updates during its first quarter financial results in early May.
Workplace and Community
We are committed to ensuring the safety and well-being of our employees and their families, as well as the communities in which we serve. In March, the company enacted new internal policies to protect its staff and mitigate the spread of COVID-19.
- To minimize exposure, Neurocrine Biosciences implemented a Work from Home Policy for all employees except certain key essential members involved in business-critical activities.
- For business-critical employees, we have implemented safety measures designed to comply with federal, state, and local guidelines.
- Our customer-facing personnel are utilizing remote technologies to ensure continued support for patients and healthcare professionals.
- We have donated supplies to San Diego area hospitals to support our local community’s preparedness and response to COVID-19.
NBIX has a gross margin of 99.10% and an operating margin of 9.20% while its profit margin remained 4.70% for the last 12 months. Its earnings per share (EPS) expected to touch remained 74.70% for this year.
The company has 96.44M of outstanding shares and 87.53M shares were floated in the market. According to the most recent quarter its current ratio was 1.5 that represents company’s ability to meet its current financial obligations. The price moved ahead of 0.72% from the mean of 20 days, -9.21% from mean of 50 days SMA and performed -12.41% from mean of 200 days price. Company’s performance for the week was -3.12%, -9.73% for month and YTD performance remained -20.20%.